FDA 已授予 Shigella4V (S4V) 快速通道资格，这是世界上临床最先进的四价生物共轭志贺氏菌病候选疫苗，Valneva 从 LimmaTech 获得了该疫苗的全球独家许可。 专业疫苗公司Valneva SE （纳斯达克股票代码：VALN ...

S4V2 will be tested for safety and preliminary efficacy in approximately 120 healthy Shigella -naïve participants aged 18 to 50 years at three sites in the United States. The study, sponsored and ...

Due to multidrug-resistant strains, shigellosis has become difficult to treat. Shigella4V (S4V) is a tetravalent bioconjugate vaccine candidate that includes O-antigen-polysaccharides of the most ...

Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered ...

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc.

In other experiments, we have found that plasmid DNA can be precipitated in the presence of up to 200 mM NaCl using 10 mM of the (more potent) tetravalent spermine. Figure 2: Precipitation by ...

Takeda Malaysia’s dengue tetravalent vaccine (live attenuated) Qdenga was officially launched on Tuesday (June 11). The vaccine, approved by the Drug Control Authority (DCA), is designed to ...

PETALING JAYA: Malaysia’s defence against dengue fever has been strengthened with the launch of the country's first vaccine against the disease. Takeda Malaysia’s dengue tetravalent vaccine ...

With the end of 2024 approaching, what could be more natural than to figure out the top stocks for the rest of the year?

GlycoMimetics (GLYC) announced it has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company.